CMV reactivation following megadose haploidentical TCD (following CD3/CD19 depletion) HSCT. (A) Immune resolution of CMV reactivation as indicated by viral DNA titer at different time points. (B) Lymphocyte subset reconstitution in peripheral blood, and time points of FACS analysis of CMV-specific T cells. (C) Enumeration of CMV-specific CD8⁺ T cells with the Dextramer CMV kit 55 days posttransplant. The host-type anti-CMV CD3⁺/CD8⁺/HLA-A02 was present at 214 cells/µL (vs 0 for donor-type CD3⁺/CD8⁺/HLA-B35/µL).